Market research
EZB.F Enzo Biochem, Inc
F EUR Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 26.%
- Beta
- 1.24
Profile
Company facts
- Exchange
- F
- Currency
- EUR
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- ISIN
- US2941001024
- Market cap
- 30M
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 26.%
- Beta
- 1.24
About
About Enzo Biochem, Inc
Enzo Biochem, Inc., a life sciences company, engages in the labeling and detection technologies from DNA to whole cell analysis in the United States and internationally. The company offers labels, dyes, antibodies, genomic probes, immunoassays, biochemicals, and proteins are used to label, detect, and visualize a biological target of interest in drug discovery exploration and drug development process development. Its proprietary products and technologies play roles in translational research and drug development areas, including cell biology, genomics, assays, immunohistochemistry, and small molecule chemistry. The company licenses its technology. It serves academic researchers, clinical researchers, biotechnology and pharmaceutical companies, and diagnostic manufacturers. Enzo Biochem, Inc. was incorporated in 1976 and is headquartered in Farmingdale, New York. As of August 20, 2025, Enzo Biochem, Inc. was taken private.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the EZB.F discussion.
5 years, 5 months ago
Enzo Biochem, Inc is currently in a long term uptrend where the price is trading 9.0% above its 200 day moving average.
From a valuation standpoint, the stock is 99.9% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 1.7.
Enzo Biochem, Inc's total revenue rose by 62.3% to $31M since the same quarter in the previous year.
Its net income has increased by 129.9% to $2M since the same quarter in the previous year.
Finally, its free cash flow grew by 78.2% to $-1M since the same quarter in the previous year.
Based on the above factors, Enzo Biochem, Inc gets an overall score of 5/5.